Valuation
- Market cap
- 6,950,509,000
- Revenue TTM
- $0
- Net income TTM
- $-505,610,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,022,100
- Avg volume
- 1,293,500
- Day's range
- $33.21 – $34.24
- Shares out
- 206,553,000
- Stochastic %K
- 21%
- Beta
- 0.84
- Analysts
- Strong Sell
- Price target
- $48.05
Company profile
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. T...
Show more
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 917 410 3120
- Website
- https://immunovant.com
- Address
- 1000 Park Forty Plaza, Suite 210, Durham, United States
Latest news
No headlines yet.
